Cargando…

Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers

BACKGROUND: The neutrophil to lymphocyte ratio (NLR) is known to be prognostic for patients with advanced cancers treated with immune checkpoint inhibitors (ICI), but has generally been evaluated as a single threshold value at baseline. We evaluated NLR at baseline and within first month during trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Mingjia, Spakowicz, Daniel, Burkart, Jarred, Patel, Sandip, Husain, Marium, He, Kai, Bertino, Erin M., Shields, Peter G., Carbone, David P., Verschraegen, Claire F., Presley, Carolyn J., Otterson, Gregory A., Kendra, Kari, Owen, Dwight H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751277/
https://www.ncbi.nlm.nih.gov/pubmed/31367835
http://dx.doi.org/10.1007/s00432-019-02982-4
_version_ 1783452589674725376
author Li, Mingjia
Spakowicz, Daniel
Burkart, Jarred
Patel, Sandip
Husain, Marium
He, Kai
Bertino, Erin M.
Shields, Peter G.
Carbone, David P.
Verschraegen, Claire F.
Presley, Carolyn J.
Otterson, Gregory A.
Kendra, Kari
Owen, Dwight H.
author_facet Li, Mingjia
Spakowicz, Daniel
Burkart, Jarred
Patel, Sandip
Husain, Marium
He, Kai
Bertino, Erin M.
Shields, Peter G.
Carbone, David P.
Verschraegen, Claire F.
Presley, Carolyn J.
Otterson, Gregory A.
Kendra, Kari
Owen, Dwight H.
author_sort Li, Mingjia
collection PubMed
description BACKGROUND: The neutrophil to lymphocyte ratio (NLR) is known to be prognostic for patients with advanced cancers treated with immune checkpoint inhibitors (ICI), but has generally been evaluated as a single threshold value at baseline. We evaluated NLR at baseline and within first month during treatment in patients who received ICI for advanced cancer to evaluate the prognostic value of baseline and of changes from baseline to on-treatment NLR. METHODS: A retrospective review of patients with advanced cancer treated with ICI from 2011 to 2017 at the Ohio State University was performed. NLR was calculated at the initiation of ICI and repeated at median of 21 days. Overall survival (OS) was calculated from the initiation of ICI to date of death or censored at last follow-up. Significance of Cox proportional hazards models were evaluated by log-rank test. Calculations were performed using the survival and survminer packages in R, and SPSS. RESULTS: 509 patients were identified and included in the analysis. Patients with baseline and on-treatment NLR < 5 had significantly longer OS (P < 0.001). The change in NLR overtime was a predictor of OS and was observed to be non-linear in nature. This property remained statistically significant with P < 0.05 after adjusting for age, body mass index, sex, cancer type, performance status, and days to repeat NLR measurement. Patients with a moderate decrease in NLR from baseline had the longest OS of 27.8 months (95% CI 21.8–33.8). Patients with significant NLR decrease had OS of 11.4 months (95% CI 6.1–16.7). Patients with a significant increase in NLR had the shortest OS of 5.0 months (95% CI 0.9–9.1). CONCLUSIONS: We confirmed the prognostic value of NLR in patients with advanced cancer treated with ICIs. We found that change in NLR over time is a non-linear predictor of patient outcomes. Patients who had moderate decrease in NLR during treatment with ICI were found to have the longest survival, whereas a significant decrease or increase in NLR was associated with shorter survival. To our knowledge, this is the first study to demonstrate a non-linear change in NLR over time that correlates with survival.
format Online
Article
Text
id pubmed-6751277
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-67512772019-10-04 Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers Li, Mingjia Spakowicz, Daniel Burkart, Jarred Patel, Sandip Husain, Marium He, Kai Bertino, Erin M. Shields, Peter G. Carbone, David P. Verschraegen, Claire F. Presley, Carolyn J. Otterson, Gregory A. Kendra, Kari Owen, Dwight H. J Cancer Res Clin Oncol Original Article – Clinical Oncology BACKGROUND: The neutrophil to lymphocyte ratio (NLR) is known to be prognostic for patients with advanced cancers treated with immune checkpoint inhibitors (ICI), but has generally been evaluated as a single threshold value at baseline. We evaluated NLR at baseline and within first month during treatment in patients who received ICI for advanced cancer to evaluate the prognostic value of baseline and of changes from baseline to on-treatment NLR. METHODS: A retrospective review of patients with advanced cancer treated with ICI from 2011 to 2017 at the Ohio State University was performed. NLR was calculated at the initiation of ICI and repeated at median of 21 days. Overall survival (OS) was calculated from the initiation of ICI to date of death or censored at last follow-up. Significance of Cox proportional hazards models were evaluated by log-rank test. Calculations were performed using the survival and survminer packages in R, and SPSS. RESULTS: 509 patients were identified and included in the analysis. Patients with baseline and on-treatment NLR < 5 had significantly longer OS (P < 0.001). The change in NLR overtime was a predictor of OS and was observed to be non-linear in nature. This property remained statistically significant with P < 0.05 after adjusting for age, body mass index, sex, cancer type, performance status, and days to repeat NLR measurement. Patients with a moderate decrease in NLR from baseline had the longest OS of 27.8 months (95% CI 21.8–33.8). Patients with significant NLR decrease had OS of 11.4 months (95% CI 6.1–16.7). Patients with a significant increase in NLR had the shortest OS of 5.0 months (95% CI 0.9–9.1). CONCLUSIONS: We confirmed the prognostic value of NLR in patients with advanced cancer treated with ICIs. We found that change in NLR over time is a non-linear predictor of patient outcomes. Patients who had moderate decrease in NLR during treatment with ICI were found to have the longest survival, whereas a significant decrease or increase in NLR was associated with shorter survival. To our knowledge, this is the first study to demonstrate a non-linear change in NLR over time that correlates with survival. Springer Berlin Heidelberg 2019-07-31 2019 /pmc/articles/PMC6751277/ /pubmed/31367835 http://dx.doi.org/10.1007/s00432-019-02982-4 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article – Clinical Oncology
Li, Mingjia
Spakowicz, Daniel
Burkart, Jarred
Patel, Sandip
Husain, Marium
He, Kai
Bertino, Erin M.
Shields, Peter G.
Carbone, David P.
Verschraegen, Claire F.
Presley, Carolyn J.
Otterson, Gregory A.
Kendra, Kari
Owen, Dwight H.
Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers
title Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers
title_full Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers
title_fullStr Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers
title_full_unstemmed Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers
title_short Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers
title_sort change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers
topic Original Article – Clinical Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751277/
https://www.ncbi.nlm.nih.gov/pubmed/31367835
http://dx.doi.org/10.1007/s00432-019-02982-4
work_keys_str_mv AT limingjia changeinneutrophiltolymphocyteratioduringimmunotherapytreatmentisanonlinearpredictorofpatientoutcomesinadvancedcancers
AT spakowiczdaniel changeinneutrophiltolymphocyteratioduringimmunotherapytreatmentisanonlinearpredictorofpatientoutcomesinadvancedcancers
AT burkartjarred changeinneutrophiltolymphocyteratioduringimmunotherapytreatmentisanonlinearpredictorofpatientoutcomesinadvancedcancers
AT patelsandip changeinneutrophiltolymphocyteratioduringimmunotherapytreatmentisanonlinearpredictorofpatientoutcomesinadvancedcancers
AT husainmarium changeinneutrophiltolymphocyteratioduringimmunotherapytreatmentisanonlinearpredictorofpatientoutcomesinadvancedcancers
AT hekai changeinneutrophiltolymphocyteratioduringimmunotherapytreatmentisanonlinearpredictorofpatientoutcomesinadvancedcancers
AT bertinoerinm changeinneutrophiltolymphocyteratioduringimmunotherapytreatmentisanonlinearpredictorofpatientoutcomesinadvancedcancers
AT shieldspeterg changeinneutrophiltolymphocyteratioduringimmunotherapytreatmentisanonlinearpredictorofpatientoutcomesinadvancedcancers
AT carbonedavidp changeinneutrophiltolymphocyteratioduringimmunotherapytreatmentisanonlinearpredictorofpatientoutcomesinadvancedcancers
AT verschraegenclairef changeinneutrophiltolymphocyteratioduringimmunotherapytreatmentisanonlinearpredictorofpatientoutcomesinadvancedcancers
AT presleycarolynj changeinneutrophiltolymphocyteratioduringimmunotherapytreatmentisanonlinearpredictorofpatientoutcomesinadvancedcancers
AT ottersongregorya changeinneutrophiltolymphocyteratioduringimmunotherapytreatmentisanonlinearpredictorofpatientoutcomesinadvancedcancers
AT kendrakari changeinneutrophiltolymphocyteratioduringimmunotherapytreatmentisanonlinearpredictorofpatientoutcomesinadvancedcancers
AT owendwighth changeinneutrophiltolymphocyteratioduringimmunotherapytreatmentisanonlinearpredictorofpatientoutcomesinadvancedcancers